Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 6/20 | 0.59 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.40 |
| ▸ | EDNRB | P24530 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.38 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6067801 | 0.88 | METAP1 (0.46) | METAP1SRD5A1SRD5A2DGAT1CYP19A1 | |
| SCHEMBL11219733 | 0.85 | METAP1 (0.57) | METAP1SRD5A1SRD5A2CYP19A1EDNRB | |
| SCHEMBL9048859 | 0.83 | CYP19A1 (0.58) | METAP1DGAT1CYP19A1ITGB3ITGA2B | |
| SCHEMBL24182315 | 0.83 | METAP1 (0.64) | METAP1SRD5A1SRD5A2CYP19A1CYP26A1 | |
| SCHEMBL6268218 | 0.82 | HTR2C (0.51) | METAP1DGAT1CYP19A1ITGB3ITGA2B | |
| SCHEMBL10756226 | 0.82 | CYP26A1 (0.45) | METAP1DGAT1CYP19A1ITGB3ITGA2B | |
| SCHEMBL7072860 | 0.82 | METAP1 (0.59) | METAP1SRD5A1SRD5A2DGAT1CYP19A1 | |
| SCHEMBL6272399 | 0.78 | METAP1 (0.65) | METAP1CYP19A1CYP26A1 | |
| SCHEMBL10689573 | 0.78 | METAP1 (0.58) | METAP1CYP19A1CYP26A1 | |
| SCHEMBL6695612 | 0.78 | METAP1 (0.57) | METAP1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2723332-B1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| EP-2723332-B1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| US-9242929-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242929-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242929-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) | 2015-10-29 | — | — | US | disclosed |
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) | 2015-10-29 | — | — | US | disclosed |
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) | 2015-10-29 | — | — | US | disclosed |
| WO-2012162127-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-11-29 | — | — | WO | disclosed |
| EP-0346107-B1 | Arylfluoroalkenamides and their use as pesticides | ROUSSEL UCLAF (FR) | 1995-09-13 | — | — | EP | disclosed |
| US-5180737-A | Insecticides, nematocides or anthelmintics | ROUSSEL UCLAF (FR) | 1993-01-19 | — | — | US | disclosed |
| EP-0346107-A2 | Arylfluoroalkenamides and their use as pesticides | ROUSSEL UCLAF (FR) | 1989-12-13 | — | — | EP | disclosed |
| US-4443626-A | ANTIINFLAMMATORY, ANTIALLERGENS, ANALGESICS, ANTICOAGULANTS, ANTIPRETICS, OR ANTICHOLESTEROL AGENTS | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1984-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | DGAT1, DGAT2, LCAT | METAP1 1077/4885SRD5A1 637/4885SRD5A2 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.